Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Oct 2013

Rexer Brent N, Ghosh Ritwik, Narasanna Archana, Estrada Mónica Valeria, Chakrabarty Anindita, Song Youngchul, Engelman Jeffrey A, Arteaga Carlos L

Abstract excerpt

PURPOSE: Mutations in receptor tyrosine kinase (RTK) genes can confer resistance to receptor-targeted therapies. A T798M mutation in the HER2 oncogene has been shown to confer resistance to the tyrosine kinase inhibitor (TKI) lapatinib. We studied the mechanisms of HER2-T798M-induced resistance to identify potential strategies to overcome that resistance. EXPERIMENTAL DESIGN: HER2-T798M was stably expressed in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Catalysis
Share to Cell Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Amplification

Share to Ligands

Share to Phosphatidylinositol 3-Kinases

Share to Receptor, ErbB-2

Share to Receptor, ErbB-3

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 23948973
DOI: 10.1158/1078-0432.CCR-13-1038
PMCID: PMC3809918

Genes

EGFR
EGF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.PMID 23948973Read ↗

EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.Semantic proximity Read ↗

An insertion mutation of ERBB2 enhances breast cancer cell growth and confers resistance to lapatinib through AKT signaling pathway.Semantic proximity Read ↗

HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer.Semantic proximity Read ↗

Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast CancerSemantic proximity Read ↗

Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.Semantic proximity Read ↗

Activating HER2 mutations in HER2 gene amplification negative breast cancer.Semantic proximity Read ↗

Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations.Semantic proximity Read ↗

Rac Inhibition As A Novel Therapeutic Strategy for EGFR/HER2 Targeted Therapy Resistant Breast CancerSemantic proximity Read ↗

AYVM to AYMM Transition on HER2 Exon 20 Insertion Induces Tyrosine Kinase Inhibitor Resistance in NSCLC.Semantic proximity Read ↗

Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.Semantic proximity Read ↗

HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway.Semantic proximity Read ↗

Src mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma models.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.